PRO 1135
Alternative Names: PRO-1135Latest Information Update: 27 May 2024
At a glance
- Originator ProfoundBio
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 21 May 2024 ProfoundBio has been acquired by Genmab
- 21 Sep 2022 Preclinical trials in Solid tumours in China (Parenteral) (ProfoundBio pipeline, September 2022)
- 16 Jul 2021 Early research in Solid tumours in China (Parenteral) (ProfoundBio pipeline, July 2021)